Trials / Terminated
TerminatedNCT02013765
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of intravenous Herceptin in patients with metastatic urothelial cancer with disease progression during platinum-based chemotherapy. The anticipated time on study treatment is until disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | trastuzumab | Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks. |
Timeline
- Start date
- 2001-01-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2013-12-17
- Last updated
- 2014-09-25
- Results posted
- 2014-09-25
Locations
7 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02013765. Inclusion in this directory is not an endorsement.